1,000,000 Shares in Assembly Biosciences, Inc. $ASMB Bought by Commodore Capital LP

Commodore Capital LP bought a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,000,000 shares of the biopharmaceutical company’s stock, valued at approximately $25,600,000. Assembly Biosciences accounts for about 1.2% of Commodore Capital LP’s investment portfolio, making the stock its 25th largest position. Commodore Capital LP owned about 0.13% of Assembly Biosciences as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its position in Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the period. ADAR1 Capital Management LLC purchased a new stake in shares of Assembly Biosciences in the third quarter worth about $485,000. Acadian Asset Management LLC boosted its stake in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Ellsworth Advisors LLC acquired a new stake in Assembly Biosciences during the third quarter worth about $852,000. Finally, Palumbo Wealth Management LLC grew its holdings in Assembly Biosciences by 86.4% during the third quarter. Palumbo Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock worth $891,000 after acquiring an additional 16,131 shares during the period. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Trading Down 0.7%

Shares of ASMB opened at $28.11 on Friday. The firm has a market cap of $444.70 million, a P/E ratio of -5.87 and a beta of 1.11. Assembly Biosciences, Inc. has a 12 month low of $7.75 and a 12 month high of $39.71. The stock’s 50 day moving average is $28.50 and its two-hundred day moving average is $29.51.

Analyst Ratings Changes

A number of research analysts have issued reports on ASMB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Mizuho set a $40.00 target price on shares of Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, December 22nd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.75.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.